AS
NAGE

Altshuler Shaham’s Niagen Bioscience NAGE Stock Holding History

Altshuler Shaham’s Portfolio NAGE Stock Details NAGE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-5,681
Closed -$23K – 478
2020
Q3 		$23K Buy
5,681
+1,504
+36% +$7.25K ﹤0.01% 318
2020
Q2 		$19K Buy
+4,177
New +$18.7K ﹤0.01% 266

Other funds holding NAGE

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
IC
Iconiq Capital San Francisco, California $4.46B AUM 22.86% 1-Year Est. Return
TCM
Tieton Capital Management Yakima, Washington $299M AUM 54.55% 1-Year Est. Return
UIC
Uniplan Investment Counsel Milwaukee, Wisconsin $974M AUM 21.37% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
SA
Sycale Advisors New York $201M AUM 2.35% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Altshuler Shaham's NAGE Position: Q4 2020 in Review

Altshuler Shaham sold out of Niagen Bioscience (NAGE) in Q4 2020, closing a stake of 5,681 shares — an estimated $23K sold.

Altshuler Shaham first reported a position in NAGE in Q2 2020 and held it in 2 quarters. The position peaked at $23K in Q3 2020. 83 funds tracked by Wall St. Rank hold NAGE as of Q4 2020.

  • Altshuler Shaham reported no remaining Niagen Bioscience position as of Q4 2020 after selling out during the quarter.
  • Altshuler Shaham sold 5,681 Niagen Bioscience shares in Q4 2020, an estimated $23K.
  • Altshuler Shaham first reported a position in Niagen Bioscience in Q2 2020 and held it in 2 quarters.
  • Altshuler Shaham's Niagen Bioscience position peaked at $23K in Q3 2020.
  • 83 funds tracked by Wall St. Rank held Niagen Bioscience as of Q4 2020.

Based on Altshuler Shaham's 13F filing for Q4 2020, filed 16 Feb 2021.